BACKGROUND: Beyond their role in hemostasis and thrombosis, platelets are also important mediators of inflammation by the release of hundreds of factors stored in their α-granules. Mutations in Nbeal2 cause gray platelet syndrome (GPS), characterized by the lack of platelet α-granules. This study aims to evaluate the immunological (proinflammatory) effects of platelet α-granules.
STUDY DESIGN AND METHODS:
We performed an experiment using Nbeal2 −/− mice, the mouse model of
GPS. Systemic inflammation was induced by intravenous injection of lipopolysaccharide (LPS).
Inflammatory response was assessed by quantification of inflammatory soluble factors and platelet biological response modifiers.
RESULTS:
The lack of Nbeal2 (in Nbeal2 −/− mice, compared with controls) significantly reduced the recruitment of circulating neutrophils and monocytes. Moreover, after LPS injection, there was a significant increase in neutrophil and monocyte counts in control animals, compared with Nbeal2 −/− mice. The control of inflammation, evaluated by the production of antiinflammatory cytokines, appeared to be greater in Nbeal2 −/− mice compared with controls. Conversely, the production of certain inflammatory-soluble mediators known to characterize normal platelet secretion, such as soluble CD40 ligand (sCD40L), was decreased under experimental inflammation in Nbeal2 −/− mice.
CONCLUSIONS:
These results show that α-granules play a direct role in platelet-mediated inflammation balance, confirming the need to further investigate platelet-associated inflammatory pathophysiology and inflammatory adverse events related to blood transfusion. ; and numerous cytokine and chemokine receptors that are essential in cell migration and communication. 5 Therefore, the role of platelets in inflammation is not limited to the expression of the multiple aforementioned receptors that primarily sense pathogens, relying also on inflammatory soluble factors stored in the α-granules and released on secretion, 6 such as CD62P, CD40L, platelet factor 4 (PF4), macrophage inflammatory proteins (MIP)-1α, regulated upon activation, normal T cell (RANTES), and interleukin (IL)-1. Most soluble factors stored in α-granules are proinflammatory 7 ; however, many studies also suggest platelets have an anti-inflammatory role. Indeed, higher levels of tumor necrosis factor-α (TNF-α), IL-6, and interferon-γ (IFN-γ) have been observed in sera and plasma in the absence of platelets. 8, 9 Moreover, the transfusion inflammatory reaction in the vascular compartment involves endothelial cell activation because of cell-cell interactions and inflammatory soluble factors infused with the blood products. Furthermore, platelets can regulate the inflammatory response of blood neutrophils by influencing the expression of macrophage receptor-1 (Mac-1) on their surface, notably through platelet integrin glycoprotein (GP) Ib to GP IX exposure. 9 The balance between the proinflammatory and anti-inflammatory factors stored in the α-granules and the platelet response through the TLR and chemokine receptors should, thus, determine the overall role of platelets in inflammation. Gray platelet syndrome (GPS) is a rare platelet bleeding disorder caused by loss-of-function mutations in NBEAL2 and characterized by a low platelet count, a lack of platelet α-granules, and early myelofibrosis. Deletion of its murine ortholog, Nbeal2, recapitulates all major features of GPS. Mouse Nbeal2 −/− platelets have a significant decrease, or an almost complete absence, in α-granule proteins, such as PF4, vWF, and P-selectin, [10] [11] [12] [13] with a potential imbalance of inflammation. In fact, Nbeal2 −/− mice are more vulnerable to bacterial (Staphylococcus aureus) and viral (murine cytomegalovirus) infection. 14 The objective was, therefore, to investigate the effect of platelet α-granule content on the amplification or down regulation of lipopolysaccharide (LPS)-induced systemic inflammation in Nbeal2 −/− mice, to reveal the proinflammatory and anti-inflammatory balance.
MATERIALS AND METHODS

Mice
Adult, male, C57BL6 mice, aged between 8 and 13 weeks, were used. For each experiment, a minimum of six mice were used. The mice were randomly distributed into different groups (phosphate-buffered saline 
LPS challenge
Mice were intravenously injected with LPS extracted from Escherichia coli (0111) (Sigma Aldrich) used at 10 mg/kg, or with PBS (control). Mice were monitored for 5 hours. The surviving mice were then euthanized in a carbon dioxide chamber, and blood was collected in acid citrate-dextrose (ACD) (Sigma Aldrich).
Cell counting
Blood was collected in ACD solution. Full blood counts were measured using a "scil Vet abc" instrument (scil Vet abc). Plasma was obtained by centrifugation and frozen at −80 C until used.
Inflammatory soluble factors and platelet biological response modifier immunoassay
The mouse biological response modifier (BRM) magnetic 
Statistical tests
Statistical analyses were performed using GraphPad Prism 5 software (GraphPad 
RESULTS
Inflammatory cell recruitment changes dependent on NBEAL2 protein expression
First, the circulating cell count revealed a significant threefoldand fourfold increase in the neutrophil and monocyte counts, respectively, in Nbeal2 −/− mice compared with control mice.
The effect of LPS intravenous injection was then assessed, demonstrating that LPS injection significantly increased the number of monocytes and reduced the number of platelets and circulating lymphocytes in both WT and Nbeal2 −/− mice.
Reciprocally, the number of neutrophils significantly increased in WT mice after LPS injection, but not in Nbeal2 −/− mice ( Fig. 1A and 1B) . The fold change of the cell populations before and after LPS injection revealed a significant increase in the neutrophil and monocyte counts in control animals compared with Nbeal2 −/− mice (Fig. 1C) . These results show that Nbeal2 −/− mice mobilize leukocytes (neutrophils and monocytes) less efficiently than WT mice after LPS-induced systemic inflammation. A likely explanation for this is that Nbeal2
mice have a limited capacity for secreting proinflammatory mediators capable of synergizing at the systemic level.
Indeed, it has already been shown that platelets, by the release of a multitude of soluble mediators contained in the α-granules, play an essential role in attracting and capturing leukocytes.
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An anti-inflammatory pattern is revealed in Nbeal2 −/− mice after LPS injection
The purpose was to evaluate the influence of platelet secretion on inflammation evaluated through cytokine/chemokine production from inflammatory cells. The fold increase in numbers of cells after LPS injection for each condition was determined (C). Data are presented as means (n = 6-9). *p < 0.05, **p < 0.01, and ***p < 0.001 represent differences between Nbeal2 −/− groups. †p < 0.05, † †p < 0.01, and † † †p < 0.001 represent differences between WT groups. #p < 0.05, ##p < 0.01, and ###p < 0.001 represent differences between PBS groups. §p < 0.05, § §p < 0.01, and § § §p < 0.001 represent differences between LPS groups.
inflammatory BRM, 15 ) were only observed in Nbeal2 −/− mice after systemic LPS injection (Table 1) , which correlated with their fold increase ( Fig. 2A) . In summary, under systemic inflammatory conditions, Nbeal2 −/− mice show a more sustained anti-inflammatory response normally hidden or limited in WT animals. These results could, therefore, support the possibility that the secretion of platelet α-granule products can change the secretory pattern of inflammatory cells and balance proinflammatory and anti-inflammatory BRMs and, overall, inflammation. Value quantification for each soluble factor in plasma was determined through a multiplex assay for each group of mice. The unit is pg/mL. Data are presented as means AE SEM (n = 6-9). * p < 0.05, ** p < 0.01, and *** p < 0.001 represent differences between Nbeal2−/− groups. † p < 0.05, † † p < 0.01, and † † † p < 0.001 represent differences between WT groups. # p < 0.05, ## p < 0.01, and ### p < 0.001 represent differences between PBS groups. One-way ANOVA revealed no statistical difference between LPS groups. bFGF = basic fibroblast growth factor.
Circulating blood cells compensate for the decrease in proinflammatory platelet-released factors in Nbeal2 −/− mice, except for sCD40L
Platelets and other blood and vascular cells secrete BRMs, such as IL-1β, KC, MCP-1, MIP-1α, RANTES, VEGF, and sCD40L, under physiological conditions and, to a greater degree, on stimulation. Although sustained production of IL-1β, 17 KC, 18 MCP-1, 19 MIP-1α, 20 RANTES, 19 and VEGF 21 is a common feature of platelets and other cells, sCD40L is mostly secreted by platelets. 22 It was, therefore, investigated whether the lack of platelet secretion, particularly for these seven soluble factors, could be compensated by other blood cells in Nbeal2 −/− mice. Concentrations of IL-1β, KC, MCP-1, MIP-1α, RANTES, and VEGF, measured in blood plasma, were significantly increased after stimulation induced by LPS injection in both WT and Nbeal2 −/− mice (Table 1) . These results indicate that other inflammatory blood cells have a potential compensatory capacity for secretion. However, sCD40L followed a different pattern, as observed by a 2.5-fold increase in its levels in PBS-injected Nbeal2 −/− mice when compared with control animals ( Fig. 2A and Table 1 ). sCD40L follows a pattern previously observed with other factors released by platelets, such as platelet factor 4 (PF4) and B-thromboglobulin (BTG), which have been found at higher levels in plasma of patients with GPS. 23 In addition, CD40L expression might be greater in Nbeal2
MKs than in WT cells, as has been reported for other proinflammatory chemokines. 10 We furthermore cannot exclude the possibility that the expression of CD40L in cells other than platelets may influence its serum levels.
The increased concentration of sCD40L may, therefore, be the consequence of a significant expression of certain proteins by the MKs or a lack of clearance of the plasma. Last, this increased concentration of sCD40L, evidenced in nonstimulated Nbeal2 −/− mice, is likely to partially explain the high baseline count of circulating neutrophils and monocytes ( Fig. 1A and 1B) . Indeed, CD40L and its agonist form sCD40L typically participate in leukocyte recruitment, notably by binding leukocyte CD40 and Mac-1 receptors. 24 Under inflammation induced through LPS intravenous injection, sCD40L levels increased in WT mice in contrast to Nbeal2 −/− mice (Fig. 2B) , which seems to correlate with the limitation of neutrophil and monocyte recruitment in control (Fig. 1C) . The secretion of certain platelet BRMs, 25 such as sCD62P, vWF, PF4, and fibrinogen, is reduced in Nbeal2 −/− mice, [10] [11] [12] [13] which may contribute to the increased concentration of antiinflammatory factors observed in these mice ( Fig. 2A) . In this study, a comparable proinflammatory cytokine/chemokine secretion pattern was observed in Nbeal2-gene deficiency and WT conditions, except for sCD40L secretion. Nevertheless, the anti-inflammatory profile was greater when mice lacked α-granules and were stimulated with intravenous LPS.
DISCUSSION
These observations are consistent with a recent study showing that the lack of NBEAL2 protein expression in mice increases their vulnerability to bacterial infection. 14 compensatory secretion. We cannot exclude a possible role of nonimmune cells, such as endothelial cells, in the release of immunomodulatory factors. 26 Platelet concentrates are known to provide a higher rate of adverse recipient reactions than other blood components. Cytokine accumulation during platelet storage may result in increased risk of transfusion reactions. Our understanding of the molecular mechanisms of secretion and the genetic regulation of granule biogenesis remains incomplete. In the present report, we expand our understanding of how platelets balance anti-inflammatory and proinflammatory factors to regulate inflammation. In an elegant approach, Deppermann et al. 11, 12 show that a deficiency in platelet α-granules and dense granules results in impaired vascular integrity during thromboinflammatory brain infarction but not in experimental inflammation of the skin or lung. This indicates that the mechanisms by which platelets maintain vascular integrity differ between inflamed organs.
Moreover, these results demonstrate that platelet granule release safeguards hemostasis during stroke injury. Plateletspecific mediators released from platelets (especially from α-granules) can themselves promote inflammation. Such platelet-specific mediators can regulate endothelial activation and migration to sites of vascular lesions. Platelets have the potential to modulate vascular permeability and integrity. In the context of transfusion, adverse reactions depend not only on the blood products but also on patients' genetic backgrounds and underlying pathological conditions. Further investigation is needed to understand the extent to which platelet components affect patients and their inflammatory status, and future studies using platelet-specific knockouts of α-granule-derived mediators will enhance our understanding of the role of platelets in adverse events related to blood transfusion.
